Dren Bio

Clinical-stage biotech developing antibodies that deplete disease-causing cells, for oncology, hematology and autoimmune disease.

View on the globe

$350MEquity raised in 2025–20262025 — · 2026 $350M · 1 equity round
$475MEquity raised, all time3 equity rounds on record
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 3 rounds from 16 Oct 2020 to 29 Oct 2026, $475M equity disclosed.16 Oct 2020: Series A, $60M; 14 Jun 2022: Series B, $65M; 29 Oct 2026: Private financing, $350M$10M$30M$100M$300M$1B2021202220232024202520262027Equity round29 Oct 2026 · Private financing · $350M · led by Juvia Group, Lightspeed Venture Partners14 Jun 2022 · Series B · $65M · led by Aisling Capital, HBM Healthcare Investments16 Oct 2020 · Series A · $60M · led by SR One, Taiho VenturesVenture · $350MSeries B · $65MSeries A · $60M
Funding history: 3 rounds from 16 Oct 2020 to 29 Oct 2026, $475M equity disclosed.16 Oct 2020: Series A, $60M; 14 Jun 2022: Series B, $65M; 29 Oct 2026: Private financing, $350M$10M$30M$100M$300M$1B2021202220232024202520262027Equity round29 Oct 2026 · Private financing · $350M · led by Juvia Group, Lightspeed Venture Partners14 Jun 2022 · Series B · $65M · led by Aisling Capital, HBM Healthcare Investments16 Oct 2020 · Series A · $60M · led by SR One, Taiho Ventures$350M$65M$60M

Funding history 3 rounds · 1 source · newest first

  1. Private financing
    Amount$350M
    Post-money—
    ✓ Confirmed
    Lead
    Juvia Group, Lightspeed Venture Partners
    Also
    Mirae Asset, General Catalyst, Cormorant Asset Management, OrbiMed, 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, ArrowMark Partners
    Note
    Series stage not disclosed in the release; described as a $350M private financing co-led by Juvia Group and Lightspeed Venture Partners.
    Sources
  2. Series B
    Amount$65M
    Post-money—
    ✓ Confirmed
    Lead
    Aisling Capital, HBM Healthcare Investments
    Also
    Pfizer, ArrowMark Partners, Revelation Partners, SR One, 8VC, Taiho Ventures, BVF Partners, Mission BioCapital, Alexandria Venture Investments
    Note
    Company said total capital raised to date exceeded $156M after this round.
    Sources
  3. Series A
    Amount$60M
    Post-money—
    ✓ Confirmed
    Lead
    SR One, Taiho Ventures
    Also
    8VC, Mission BioCapital, BVF Partners, HBM Healthcare Investments, Alexandria Venture Investments
    Note
    Release also cites a $6M seed round in 2019 led by 8VC (month not given, not recorded).
    Sources

Investors 17

  • HBM Healthcare Investments3
  • SR One3
  • Taiho Ventures3
  • Aisling Capital2
  • Juvia Group1
  • Lightspeed Venture Partners1
  • 8VC3
  • BVF Partners3
  • Mission BioCapital3
  • Alexandria Venture Investments2
  • ArrowMark Partners2
  • Cormorant Asset Management
  • General Catalyst
  • Mirae Asset
  • OrbiMed
  • Pfizer
  • Revelation Partners

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the San Carlos hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Dren Bio and its logo are trademarks of their owners, used here for identification only.